Invivyd, Inc. (IVVD)
(Delayed Data from NSDQ)
$1.81 USD
-0.03 (-1.63%)
Updated Jun 3, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IVVD 1.81 -0.03(-1.63%)
Will IVVD be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IVVD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IVVD
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
IVVD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
Other News for IVVD
Invivyd to Participate at the Jefferies Global Healthcare Conference
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
Invivyd Announces Executive Leadership Shakeup and Strategic FDA Alignment
Invivyd announces general alignment with FDA on EUAs for antibodies of COVID-19